Gentian is a Norwegian IVD company that specialises in developing and manufacturing turbidimetric assays that enable clinical lab professionals to achieve greater operational efficiency, thus providing faster patient results to clinicians. The current portfolio and pipeline of diagnostic reagents span areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine.
By leveraging both our expertise in Particle-Enhanced Turbidimetric Immunoassays (PETIA) and proprietary nanoparticle technology, we develop immunoassays that enable users to transition from traditional low volume immunology platforms to fully automated clinical chemistry instruments. The typical Gentian customer enjoys shorter turnaround times, streamlined workflows and improved cost efficiency.
2001
Served areaWorldwide
15,422,350
IPODec. 14, 2016
Stock exchange(s)Euronext Oslo